Background {#Sec1}
==========

Nontuberculous mycobacteria (NTM) are ubiquitous bacteria of environmental origin including a widely diverse number of species (\> 160), some of which cause disease in humans \[[@CR1]--[@CR3]\]. Prevalence of NTM lung diseases is unexpectedly increasing in industrialized countries, as consistently uncovered by recent studies \[[@CR3], [@CR4]\]. The key issue remains to determine whether NTM are the true and single promoter of an evolving lung disease or chronic airway colonizers, among others. To standardize the diagnosis of NTM lung disease, the guidelines for NTM diagnosis of the American Thoracic Society (ATS)/Infectious Disease Society of America (IDSA) and the British Thoracic Society (BTS) require isolation and growth of the same NTM strain on at least two separate samples from the patient \[[@CR5], [@CR6]\].

Human host and pathogenic NTM relationship is still poorly understood, as NTM virulence is highly variable from one species to another. NTM lung disease is strongly associated with pre-existing pulmonary conditions such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, idiopathic bronchiectasis, prior active tuberculosis or pneumoconiosis \[[@CR6]\]. It is also frequently associated with genetic or acquired systemic immune deficiency such as defects in the pathways of inflammatory cytokines interleukin (IL)-12, tumor necrosis factor (TNF)-α or interferon (IFN)-γ, immunosuppressive treatments (including anti-TNF-α therapy or corticosteroids), solid-organ transplantation, or acquired immune deficiency syndrome (AIDS)/human immunodeficiency virus (HIV) infection \[[@CR1]--[@CR7]\]. However, it may also occur in individuals without recognized severe immune local or systemic deficiency. In the absence of patent predisposition, NTM diseases are overrepresented among the specific morphotype of slender women with a low body fat \[[@CR8]\].

Treatment decision for NTM lung disease is challenging. There is debate as to which patients should benefit the most from treatment according to medical background, comorbidities, clinical status, radiologic features and causal NTM strain. Assessment of clinical, microbiologic, and radiologic response to treatment is not standardized as well. We focused on NTM lung diseases in adults without systemic immunodeficiency that met the ATS criteria guidelines. Based on the comparison of a group of treated and untreated patients, the primary objective was to identify the factors associated with physician decision of initiating anti-NTM treatment. Secondary objectives were to study the outcome upon treatment and to propose a standardized evaluation for the diagnosis and decision making to treatment of NTM lung diseases in adults without systemic immunodeficiency.

Methods {#Sec2}
=======

Study design and patient population {#Sec3}
-----------------------------------

We conducted a retrospective, observational, single-center study between January 2013 and February 2016 (45 months) among adults (≥ 18 year-old) without systemic immunosuppression presenting NTM lung disease. Exclusion criteria were HIV infection, cystic fibrosis, primary ciliary dyskinesia, active malignant disease, solid-organ transplantation or ongoing immunosuppressant treatments such as TNF inhibitor or high-dose corticosteroid (≥ 1 mg/kg more than 21 days). Case identification was based on cross-referencing the databases of the mycobacteria laboratory and the departments of infectious and pulmonary diseases. Patients eligible for inclusion in the NTM lung disease cohort were those who matched the criteria previously defined by the ATS/IDSA and the BTS guidelines with the minimum requirement of clinical and microbiologic following criteria: *(i)* pulmonary symptoms associated with multifocal bronchiectasis with multiple small nodules on computed tomography (CT)-scan; *(ii)* proper exclusion of other diagnoses; *(iii)* NTM-positive culture results from at least two separate expectorated sputum samples or a NTM-positive culture result from at least one bronchial wash or lavage \[[@CR5], [@CR6]\]. Patients' characteristics at diagnosis were collected in order to perform analysis on 146 selected variables: demographics; history of predisposing factors; underlying pulmonary diseases; comorbidities; pulmonary function testing; respiratory bacterial or mycological co-infection(s), which definition was similar to NTM criteria, namely positive culture isolation of the same species from at least two separate expectorated sputum samples or a positive culture result from at least one bronchial wash or lavage; immunologic status; nutritional status; clinical features; microbiologic assessment through identification of NTM species on positive NTM cultures and sample culture conversions; radiologic features on high-resolution CT-scans (fibrocavitary disease or nodular/bronchiectasis disease); prior treatment for NTM lung disease, treatment combination and duration; outcome. Because of the retrospective observational nature of the study and the lack of any modification in patients' management, the need for informed consent was waived with the authorization of the Ethics Committee of Lyon University Hospital (Comité d'Ethique, Hospices Civils de Lyon), which approved the study under the number 17--207.

Radiologic assessment {#Sec4}
---------------------

An independent expert chest radiologist, blinded to the patient information, retrospectively reviewed the CT-scans performed without injection of intravenous contrast media, assigned in random order at diagnosis and six to 24 months after treatment or during the follow up of the untreated patients. The number and size of cavity(ies) and their wall thickness were evaluated in the lung window setting. Nodular opacity(ies) (≥ 10 mm), cluster(s) of small nodules (≤ 5 mm), the tree-in-bud pattern, the presence of bronchiectasis in any of the lobes or multifocal bronchiectasis were evaluated. Based on the number and size of the lesions, the expert classified the lesions as improved, stable or worsening.

Endpoints {#Sec5}
---------

The primary endpoint was to identify the factors significantly involved in the decision of initiating anti-NTM treatment by patient referent physician. Secondary endpoints were the assessment of clinical and radiological outcomes upon anti-NTM treatment in comparison with no treatment. Based on these findings, a standardized appraisal was proposed to assist diagnosis management and treatment decision for NTM lung diseases in adults without altered systemic immunity.

Statistical analysis {#Sec6}
--------------------

Descriptive data were used to estimate the frequencies of the study variables. There were expressed as count (percentage, %) for dichotomous variables and as medians (interquartile range \[IQR\]) for continuous values. The number of missing values was excluded from the denominator. Non-parametric statistical methods Fisher exact test, χ2 test and Mann-Whitney U test were used to compare groups, where appropriate. The probability of treatment initiation over time was evaluated by Kaplan-Meier survival curve analysis, with group comparison using the log-rank (Mantel-Cox) test. Stepwise binary logistic regression analysis was used to assess the determinants for treatment initiation, expressed as odd ratios (OR) with 95% confidence intervals (95% CI). After checking the variables for interactions, variables with medical meaning and with *p*-values obtained in the univariate analysis of \< 0.15 were included in the final multivariate model. A value of *p* \< 0.05 was considered significant. All analyses were performed using SPSS software version 24.0 (SPSS. Chicago. IL).

Results {#Sec7}
=======

Out of 149 patients eligible to ATS/IDSA NTM lung disease criteria, 51 patients were included in the study, of who 25 (49%) received and 26 (51%) did not receive anti-NTM treatment (Fig. [1](#Fig1){ref-type="fig"}). The median age was 68 (interquartile range \[IQR\], 59--75) year-old with a male/female ratio of 0.76. Etiologic NTM agents were *Mycobacterium avium* (*n* = 17, 33.3%), *M. chimaerae* (*n* = 14, 27.5%), *M. xenopii* (*n* = 9, 17.6%), *M. intracellulare* (*n* = 9, 17.6%), *M. simiae* (*n* = 3, 5.9%), *M. kansasii* (*n* = 1, 2%), and *M. abscessus* (*n* = 1, 2%), with three patients having ≥2 concomitant NTM lung diseases. Importantly, the evidence of NTM lung disease has led to diagnose six underlying chronic lung diseases, of which a genetically documented cystic fibrosis in a 61 year-old women. On descriptive analysis, patient's characteristics did not significantly differ, to the exception of a lower BMI (*p* = 0.023) and a higher number of previously known NTM lung disease (*p* = 0.038) in treated versus untreated patients (Table [1](#Tab1){ref-type="table"}). Notable percentages of missing data at diagnosis have to be acknowledged for active tobacco smoking (64.7%, *n* = 33), respiratory functional testing (23.5%, *n* = 12) with a very few patients having a 6-min walk test, baseline arterial blood oxygenation levels (58.8%, *n* = 30), CT-scan follow up within 24 months after diagnosis in untreated patients (46%, *n* = 12).Fig. 1Flow chart of adult patients with nontuberculous mycobacterial lung disease without altered systemic immunity included in the study. Nontuberculous mycobacterial lung disease defined according to the American Thoracic Society/Infectious Diseases Society of America and the British Thoracic Society \[[@CR4], [@CR5]\]Table 1Patients' demographic and baseline descriptive characteristicsTreated patients (*n*=25)Untreated patients (*n*=26)*P*-valueAge, median (IQR) years65 (54-74)70 (60.8-76)0.227Gender (male)9 (36)13 (50)0.4Active smokers6 (24)6 (23)1Cumulative tobacco smoking (IQR) pack/year32.5 (28.8-52.5)40 (21.3-60)0.79BMI (IQR) kg/m^2^17.9 (16.8-19.9)19.9 (18.3-23.8)***0.023***History of tuberculosis6 (24)5 (19.2)0.74History of NTM lung disease8 (32)2 (7.7)***0.038***History of croup during infancy111Gastroesophageal reflux disease4 (16)2 (7.7)0.42History of cured malignant solid tumor1 (4)5 (19.2)0.19Diabetes mellitus02 (7.7)0.49Chronic heart failure04 (16)0.11Asthma or atopic disease6 (24)2 (7.7)0.14Chronic obstructive pulmonary disease4 (16)9 (34.6)0.19Bronchiectasis14 (56)14 (53.8)1Chronic interstitial lung disease2 (8)5 (19.2)0.42Chronic rheumatic disease6 (24)2 (7.7)0.14Autoimmune disease3 (12)4 (15.4)1History of thoracic surgery5 (20)3 (11.5)0.46Corticosteroid inhaled therapy6 (24)7 (27)1NOTE Data are No. (%) of patients, unless otherwise indicated. Variables were compared using Mann--Whitney U test, χ2 test or the Fisher exact test, where appropriateAbbreviations: IQR, interquartile range

Factors leading the patient referent physician to initiate anti-NTM treatment were assessed using bivariate analysis. Among the factors significantly associated with treatment were the BMI \< 18 kg/m^2^ (odds ratio (OR), 4.2 \[95% confidence interval (CI) 1.2--15.2\]; *p* = 0.042), prior anti-NTM treatment (OR, 5.65 \[95% CI 1.06--29.9\]; *p* = 0.042), hemoptysis (OR = 11.8 \[95% CI 1.35--102.9\]; *p* = 0.026), the presence of excavation(s) on lung CT-scan (OR, 4.8 \[95% CI 1.4--16.4\], *p* = 0.012), *Aspergillus* spp. co-infection (OR, 6.3 \[95% CI 1.8--22.2\]; *p* = 0.004) (Table [2](#Tab2){ref-type="table"}). In multivariate analysis, *Aspergillus* spp. co-infection was the single independent factor associated with anti-NTM treatment (OR, 5.3 \[95% CI 1.1--25.4\]; *p* = 0.036) (Table [3](#Tab3){ref-type="table"}).Table 2Bivariate analysis of the factors associated with treatment initiation in adult patients with nontuberculous mycobacterial lung disease without systemic immunodeficiencyTested variablesTreated patients (n=25)Untreated patients (n=26)*P-value*OR \[95% CI\]*Clinical criteria* BMI \< 18 (kg/m^2^)13/24 (54.2)5/23 (21.7)***0.026***4.25 \[1.18-15.2\] Weight loss \> 5%17 (68)10 (38.5)***0.05***3.4 \[1.07-10.77\] fatigue13 (52)7 (27)0.0712.94 \[0.9-9.46\] chronic cough16 (64)14 (54)0.5721.52 \[0.49-4.69\] night sweats5 (20)3 (11.5)0.4651.92 \[0.41-9.05\] hemoptysis8 (32)1 (3.8)***0.026***11.8 \[1.3-102.8\]*Microbiological criteria* AFB-positive sputum sample on direct examination13 (52)8 (30.8)0.1602.44 \[0.77-7.65\] NTM-positive culture NTM on lower respiratory tract sample2 (1-2.3)1 (1-1.8)***0.044*1.79 \[1-3.2\]***Functional criteria* FEV1 (L)1.6 (1.2-2.2)1.9 (1.2-2.5)0.5540.72 \[0.34-1.51\]*Immunological and nutritional status* total lymphocyte count (G/L)1.3 (1.2-1.7)1.4 (1.1-2.1)0.3880.95 \[0.86-1.04\] CD4+ lymphocyte count (%)54 (4.5-61.5)40 (37.8-44.3)***0.031*1.07 \[0.95-1.21\]** serum albumin (mg/L)39.5 (36-43)39 (33-42.5)0.4811.05 \[0.97-1.14\] serum pre-albumin (mg/L)0.21 (0.15-0.24)0.22 (0.15-0.25)0.9741.25 \[0-1.48\] vitamin D deficiency6/10 (60)6/7 (86)0.3380.25 \[0.02-2.95\]*Co-infection(s)* *Mycobacterium tuberculosis*1 (4)1 (4)0.351.04 \[0.06-17.6\] *Pseudomonas* spp.2 (8)3 (11.5)10.68 \[0.1-4.4\] *Aspergillus* spp.15 (60)5 (19.2)***0.004*6.3 \[1.8-22.2\]***Radiologic features at diagnosis* nodule(s) (≥ 10mm)12 (48)7/23 (30)0.252.11 \[0.65-6.9\] cluster(s) of micronodules (\< 5mm)16 (64)10/23 (44)0.2462.31 \[0.72-7.4\] cavitation(s)18 (72)8/23 (35)***0.019*4.82 \[1.42-16.4\]** bronchiectasis14 (56)11/23 (48)0.7731.39 \[0.45-4.3\] emphysema9 (36)11/23 (48)0.5590.61 \[0.19-1.95\]*Radiologic review* regression8/23 (35)4/13 (31)11.2 \[0.28-5.15\] stabilization9/23 (39)6/13 (46)0.7360.75 \[0.19-2.97\] worsening6/23 (26)3/13 (23)11.18 \[0.24-5.8\]NOTE Data are No. (%) of patients, unless otherwise indicated. Denominators have been stipulated for variables with missing data. Odds ratios (OR) were determined by conditional logistic regression with 95% confidence interval (95% CI)Abbreviations: AFB, acid-fast bacilli; BMI, body mass index; CI, confidence interval; FEV1, forced expiratory volume in 1 second; NTM, nontuberculous mycobacteria; OR, odds ratioTable 3Multivariate analysis of factors associated with the initiation of anti-nontuberculous mycobacteria treatmentIndependent variablesOR \[95% CI\]*P*-value*Aspergillus* spp.***5.33 \[1.1-25.5\]**0.036***weight loss \> 5%2.44 \[0.6-10.2\]0.22hemoptysis3.2 \[0.28-36.3\]0.35excavation(s)3.54 \[0.83-15.1\]0.087Abbreviations: CI, confidence interval; OR, odds ratio

The probability of treatment initiation over time according to the presence or not of targeted variables was investigated. The probability was significantly higher in case of BMI \< 18 vs. \> 18 kg/m^2^ (*p* = 0.006), of hemoptysis vs. no hemoptysis (*p* = 0.009), of *Aspergillus* spp. co-infection vs. no co-infection (*p* = 0.029), of pulmonary excavation(s) vs. no excavation (*p* = 0.005) (Fig. [2](#Fig2){ref-type="fig"}a, b, c and d, respectively). In the treated group, 21 (84%) received ≥3 anti-NTM drugs, among whom 23 (92%) received a macrolide as part of a first-line regimen. Median anti-NTM treatment duration was 36.3 (IQR, 13.1--64.4) weeks. Thirteen (52%) of the treated patients developed at least one antimicrobial-related adverse event, among which gastrointestinal disorders (*n* = 6), impaired blood cell count (*n* = 5) and cholestatic and/or cytolytic hepatitis (*n* = 4). According to physician judgment, clinical stabilization and improvement was obtained for 8 (34.8%) and 12 (52.2%) of treated patients, respectively. Patient's median follow-up from diagnosis assessment was 17.1 (IQR, 8.7--27.1) months. Eighty-five CT-scans were reviewed for comparative assessment after treatment or over the course of follow-up in the untreated subset. The median interval between the initiation of NTM treatment and the date of the assessed images was 56.7 (IQR, 43.3--97.7) weeks. Although 34.8% (*n* = 8) and 39.1% (*n* = 9) experienced regression or stabilization of their pulmonary lesions in the treated patients, these rates did not differ from the untreated patients with 30.8% (*n* = 4) and 46.2% (*n* = 6) of regression and stabilization over the course of their follow-up, respectively (Table [2](#Tab2){ref-type="table"}). Finally, all-cause mortality was not different between treated and untreated groups, although lost to follow-up was high in the untreated group (*n* = 10, 38.5%). Regarding the four patients that deceased (*n* = 3 in the treated group and *n* = 1 in the untreated group), the cause of mortality was linked to the underlying diseases rather than NTM-related mortality.Fig. 2Overall probability of anti-nontuberculous mycobacteria treatment initiation according to the presence or the absence of the following variables: **a** body mass index \< 18 kg/m^2^; **b** hemoptysis; **c** *Aspergillus* spp. co-infection; **d** lung excavation(s). Overall survival probabilities were determined by the Kaplan-Meier method and were compared by the log-rank test

Discussion {#Sec8}
==========

In the present study, treated patients were characterized by BMI \< 18 kg/m^2^, presence of hemoptysis and excavation(s), *Aspergillus* spp. co-infection, and prior anti-NTM treatment. *Aspergillus* spp. co-infection was the only independent factor associated with treatment initiation. A single study from five English centers has recently addressed the factors that influence anti-NTM treatment initiation using similar retrospective design of treated and untreated cohort comparison (2010--2014), to the exception of different inclusion criteria which allowed non-AIDS/HIV immunosuppressed patients (36 and 33% in the treated and untreated subsets, respectively) to be evaluated. In the multivariate analysis, patients had increased odds of anti-NTM treatment in case of cavitation on CT imaging, night sweats and weight loss \[[@CR9]\].

Here, three out of four criteria are part of guideline criteria leading to decision of anti-NTM treatment. They all reflect a degree of severity of NTM lung disease linked with progression of an impaired respiratory condition. The current problematic of NTM lung diseases shifts from distinguishing colonization from infection toward differentiating stable, poorly active vs. progressive active NTM disease, the latter being responsible for further structural lung damage(s). The risk/benefit analysis includes prescribing recommended long-term multidrug regimens with concerns over suboptimal cure rates and frequently reported drug-related side effects. To support these arguments, others have already shown that physician ATS/IDSA guideline adherence is moderate confirming such a trend of intuitive clinical behavior mostly based on evidence of severity and/or patent progression of the disease. A multicenter study has reported a sample of 349 US physicians treating 915 patients with *M. avium* complex (MAC) lung disease. Overall, 55% (*n* = 411) of patients with MAC lung disease received some type of anti-NTM treatment from their physician and 13% prescribed antibiotic regimens were consistent with ATS/IDSA guidelines \[[@CR10]\]. Another study conducted in France has shown that among a cohort of 31 NTM lung diseases, only 12 (38.7%) received appropriate treatment matching ATS/IDSA guidelines \[[@CR11]\]. Inappropriate prescriptions were mostly related to shorter treatment duration (6 months or less) and/or off-recommendation regimen, particularly those excluding macrolide from the combination or those using a single-drug macrolide regimen \[[@CR10], [@CR11]\]. It has to be acknowledged that guidelines specify that treatment for MAC-associated lung disease in HIV-negative individuals can be a three-times-weekly drug regimen upon culture conversion while on therapy for 1 year, which may favor treatment compliance \[[@CR5], [@CR12], [@CR13]\].

Patients with bronchiectasis and NTM lung disease have a higher prevalence of being sensitized to *Aspergillus* than patients with NTM-free bronchiectasis \[[@CR12]\]. Allergic airway manifestations in response to *Aspergillus* are termed *Aspergillus*-related lung diseases with a spectrum going from *Aspergillus*-induced hypersensitivity to the severe allergic bronchopulmonary aspergillosis (ABPA) \[[@CR14]\]. By itself, the coexistence of NTM and *Aspergillus* in lung airway justifies the need for testing *Aspergillus* serology, total serum immunoglobulin (Ig)E and *Aspergillus*-specific IgE levels as well as mycological direct examination and culture of sputum or bronchial aspirates for presence of filamentous fungi in the diagnosis algorithm of patients with NTM lung diseases. Active co-infections with NTM and *Aspergillus* spp. have also been described, in which patients with NTM lung disease develop chronic forms of pulmonary aspergillosis which definitions and management have been revisited in recent updated guidelines \[[@CR14]--[@CR17]\].

Radiographic improvement may be hampered by concomitant lung disease and the limited potential for resolution of consolidated radiologic abnormalities. A previous study has investigated radiologic response to treatment showing consistent results with those found in the present study. Although anti-NTM treatment led to an improvement or stabilization of lesions for a majority of patients, these modifications were not significantly different from the untreated group who went through CT-scan follow up indicating that anti-NTM treatment did not lead to radiological abnormalities reversion \[[@CR9]\]. The present study has strengths and limitations. The strength is the study of the largest cohort so far of NTM lung diseases in patients without systemic immunodeficiency with exhaustive data collection and blinded radiological assessment. We acknowledge the biases that contribute to mitigate conclusions from the study such as being conducted in a single center, the important differences in physician's management resulting in lack of consistency in treatment decision making, the number of missing data. In addition, the CT-scans were not performed at fixed intervals, particularly in the untreated subset of patients. Finally, treatment duration and outcome criteria were not standardized, which prevent to properly assess treatment efficacy. Useful consensus definitions for key outcome parameters to be used in the treatment of NTM lung diseases have been released very recently, which should harmonize data collection regarding NTM treatment \[[@CR18]\].

Future researches are necessary to better define criteria associated with progressive active NTM disease in the immunocompetent setting. Concretely, this preliminary study has led to implement in our institution a standardized appraisal for the diagnosis of NTM lung diseases in this particular setting (Table [4](#Tab4){ref-type="table"}). The aim is to provide a future basis for the development of a diagnosis scoring system supporting anti-NTM treatment decision. Future studies should focus as well on the most relevant CT imaging variables associated with response to treatment over time that may be applied in future clinical trials to assess treatment outcome.Table 4Standardized appraisal for patients with nontuberculous mycobacterial lung diseases without systemic immunodeficiency referred at our institutionComments*Exhaustive history record* infant respiratory diseasescroup, Influenza, measle gastro-oesophageal reflux disease atopic dermatitis eating disordersanorexia, bulimia family history of respiratory disease prior tuberculosis prior anti-NTM treatment*Environmental exposure* passive tobacco exposure active tobacco smockingPacks-per-year other toxic/drug exposure chronic alcoholismmicro-inhalations habitat characteristicsdomestic water system, allergens*Blood tests* serum albuminnutritional status serum pre-albumin vitamin D (25-OH D3) HIV serologycellular immune defect T CD4+ and CD8+ lymphocyte counts total IgG serum levelhypogammaglobulinemia total eosinophil count*Aspergillus*-related allergic lung diseases total IgE serum level *Aspergillus*-specific IgE *Aspergillus* serology galactomannan antigenemiainvasive aspergillosis Interferon-γ reactive assaylatent tuberculosis infection*Lung function testing* spirometry including FEV1lung volumes plethysmography pulse oxymetryoxygen level arterial blood gas tests 6-minutes walk teststress test*Imagery*chest X-ray lung HRCT scanMicronodules (≤ 5mm), nodules (≥ 10 mm), pulmonary consolidations, bronchiectasis, tree-in-bud images, cavity(ies)*Cytology and microbiologic tests on respiratory samples*BALF cytological compositionsputum/BALF direct examination sputum/BALF collection for bacterial cultureNon-fermenting gram-negative bacilli (*Pseudomonas aeruginosa*) sputum/BALF collection for mycological culturefilamentous fungi nasal swab/BALF collection for respiratory virus PCR screeninghuman Respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus*Specific tests depending on the setting* α-1 antitrypsin levellung emphysema sweat testcystic fibrosis CFTR gene screening airway cilia sampleprimary ciliary dyskinesia IFN-γ and IL-12 plasma levelshost predisposition to NTM diseases blood anti-IFN-γ autoantibodies IFN-γ or IL-12 gene screeningAbbreviations: BALF, bronchoalveolar lavage fluid; CFTR, cystic fibrosis transmembrane conductance regulator, FEV1, forced expiratory volume in 1 second; HRCT, high-resolution computed tomography; IFN-γ, interferon gamma; Ig, immunoglobulins; IL, interleukin

Conclusions {#Sec9}
===========

In summary, the main factors supporting anti-NTM treatment decision in immunocompetent were low BMI, hemoptysis, lung excavation(s), prior anti-NTM treatment and *Aspergillus* pp. co-infection, the latter being the only independent factor. Anti-NTM treatment did not achieve radiological abnormalities reversion, as pulmonary lesions assessment showed no difference between the treated and the untreated patients. A diagnosis of NTM lung disease in an immunocompetent patient requires investigating the presence of a chronic pulmonary underlying disease.
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